Ariad stated a total 307 patients were signed up for EPIC, a randomized, two-arm, multicenter trial designed to compare the efficacy of imatinib and ponatinib in adults with newly diagnosed chronic CML. The trial had been conducted at about 150 investigational sites in more than 20 countries. Patients had to be at least 18 years of age and CML-diagnosed within half a year before enrollment. Predicated on Stage II data, Iclusig won FDA accelerated acceptance for resistant or intolerant CML and Philadelphia-chromosome positive acute lymphoblastic leukemia patients.FEAR CAMPAIGN: The mass media used the family-friendly Disney brand to hype-up a non-existent ‘national outbreak’. The truth, like the US-based Ebola Hoax just, is that there surely is no ‘national outbreak’. The CDC is currently promoting the idea that 2014 was an archive 12 months for measles in the US with approximately 644 cases out of a US population of 320 million. What the media is not telling you is that most those 644 plus situations originated from two specific.. Biocept’s paper describes identification of different CTC phenotypes in tumor patients Biocept, Inc.